Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Correction of hypokalemia,Prevention of hypokalemia in patients at risk,Intravenous source of calories (dextrose)
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
Potassium has no true elimination half-life as it is homeostatically regulated; the terminal half-life of a potassium load is approximately 8-12 hours in healthy individuals, but this is highly variable and dependent on renal function, aldosterone status, and body stores. In anuric patients, potassium clearance is minimal, and dangerous accumulation can occur within hours.
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Potassium is not metabolized; excreted primarily by kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Primarily renal; >90% of potassium is excreted by the kidneys, with approximately 10% lost in feces. In steady state, urinary potassium excretion matches dietary intake (typically 40-120 m Eq/day). Dextrose is completely metabolized; unchanged dextrose excretion is negligible (<1% renal) in normoglycemic individuals.
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
Potassium: negligible (<2%) protein binding; it is present as free ions. Dextrose: not protein bound.
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
Potassium: Vd ~0.5 L/kg (total body water); essentially distributes throughout the entire body water. Over 98% of total body potassium is intracellular; the Vd for administered potassium is larger than that for extracellular markers due to rapid cellular uptake. Dextrose distributes into total body water (Vd ~0.6 L/kg).
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Intravenous: 100% bioavailability. Not administered by other routes for potassium repletion due to poor tolerability and absorption (e.g., oral bioavailability of potassium chloride is 80-90%, but GI irritation limits use).
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
GFR <30 m L/min: avoid use unless documented hypokalemia; maximum infusion rate 5 m Eq/h. GFR 30-50 m L/min: reduce rate to 5-10 m Eq/h. GFR >50 m L/min: standard dosing.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
No dose adjustment required for Child-Pugh class A or B. Class C: use with caution, monitor potassium levels and infusion rate; reduce maximum rate to 5 m Eq/h.
No adjustment required for hepatic impairment.
0.5-1 m Eq/kg/dose IV, infused at a rate not exceeding 0.5-1 m Eq/kg/h; maximum concentration 40 m Eq/L for peripheral infusion. Adjust based on serum potassium levels.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
Reduce initial infusion rate to 5 m Eq/h; monitor renal function and serum potassium closely due to age-related decline in GFR; maximum concentration 40 m Eq/L.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
Potassium chloride injections are concentrated and must be diluted before administration. Rapid infusion may cause fatal hyperkalemia.
No FDA black box warning.
Risk of hyperkalemia, especially in renal impairment,Monitor serum potassium and ECG during administration,Do not administer undiluted,Use with caution in patients with cardiac disease, metabolic acidosis, or hypovolemia,Extravasation risk may cause tissue necrosis
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Hyperchloremia,Conditions exacerbated by fluid overload
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
No specific food interactions. However, dietary potassium intake should be monitored when on high-dose potassium supplementation to avoid hyperkalemia. Avoid consuming large amounts of potassium-rich foods (e.g., bananas, oranges, tomatoes) without consulting a healthcare professional.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, maternal hyperkalemia or severe acidosis/fluid shifts may adversely affect fetal outcome. Trimester-specific risks not established.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Potassium and dextrose are normal constituents of breast milk. Intravenous administration results in minimal changes to milk composition. M/P ratio not applicable. Considered compatible with breastfeeding.
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No specific dose adjustments required. However, pregnant women may have increased plasma volume and altered renal function; standard dosing based on electrolyte and fluid deficits. Monitor serum potassium and glucose closely to avoid hyperkalemia or hyperglycemia.
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
Potassium chloride in dextrose 5% is an intravenous solution for correction of hypokalemia and provision of maintenance fluids. Monitor serum potassium, renal function, and ECG during infusion. Maximum infusion rate: 10-20 m Eq/hour with continuous cardiac monitoring. Avoid in severe hyperkalemia, renal failure with oliguria, or conditions with potassium retention. Use central line if concentration >60 m Eq/L. Do not administer undiluted. Incompatible with amphotericin B, cefepime, and others.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
This solution is given intravenously to replace potassium and provide hydration.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the infusion or adjust the rate on your own.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking potassium supplements or certain blood pressure medications.,Inform your provider if you feel tingling, muscle weakness, irregular heartbeat, or confusion.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCONATE, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCONATE depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, mater. CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.